Associations of Alzheimer's disease with inpatient hospital costs and quality-adjusted life years in the UK Biobank
This innovative project utilises data from the UK Biobank to examine how Alzheimer's disease, a condition affecting cognitive abilities, affects healthcare costs and quality of life. We will use multivariable models, which analyse how different factors about the disease relate to costs and life quality. However, these models might miss some hidden factors. To address this, we will also use Mendelian Randomization. This method uses genetic information—specific variations in genes related to Alzheimer's risk—as a tool to understand the disease's impact more clearly, helping to ensure our findings are robust and reliable.
With Alzheimer's cases on the rise globally due to ageing populations, understanding its economic implications is crucial for healthcare policy and intervention strategies. By generating the first evidence from the extensive UK Biobank cohort on the association between Alzheimer’s and health economic outcomes, this study will support evaluations of interventions, leading to more effective management of Alzheimer's disease, ultimately improving patient quality of life and reducing economic strain on healthcare systems.
Project lead / contact: Padraig Dixon — Nuffield Department of Primary Care Health Sciences, University of Oxford
ARC theme: Dementia Community of Practice
